Neuroblastoma was first suggested as a gene-dosage disorder in the 90s [18,19], and today the International Neuroblastoma Risk Group (INRG) uses a classification system based on several key criteria that include age, stage, tumor histology, MYCN amplification (MNA), 11q-deletion, and ploidy to define very low-, low-, intermediate- and high-risk groups according to 5-year event-free survival (EFS) [20,21]. This evidence concerns the gene MYCN and neoplasm.